Concepedia

Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Masanori Terashima, Young‐Woo Kim, Narikazu Boku, Hyun Cheol Chung, Jen‐Shi Chen, Jiafu Ji, Ta-Sen Yeh, Li‐Tzong Chen, Min‐Hee Ryu,

˜The œLancet. Gastroenterology & hepatology · 2024 · 75 citations · 29 references

DOI

Concepts

References

29

EuroQol - a new facility for the measurement of health-related quality of life

Health Policy · 1990 · 15.8K citations

, , +11

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

Pieter van Hagen, Maarten C.C.M. Hulshof, J. Jan B. van Lanschot et al. · New England Journal of Medicine · 2012 · 5.5K citations · Full text

, , +14

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.9K citations · Full text

, , +16

Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine

Shinichi Sakuramoto, Mitsuru Sasako, Toshiharu Yamaguchi et al. · New England Journal of Medicine · 2007 · 2.5K citations · Full text

, , +11

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh et al. · The Lancet · 2017 · 2.3K citations · Full text

, , +12